137 related articles for article (PubMed ID: 24183301)
1. Important treatment gaps in vascular protection for the elderly after type 2 diabetes therapy initiation.
Guénette L; Breton MC; Hamdi H; Grégoire JP; Moisan J
Can J Cardiol; 2013 Dec; 29(12):1593-8. PubMed ID: 24183301
[TBL] [Abstract][Full Text] [Related]
2. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J
Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
4. Identifying adherent patients to newly initiated statins using previous adherence to chronic medications.
Majd Z; Mohan A; Paranjpe R; Abughosh SM
J Manag Care Spec Pharm; 2021 Feb; 27(2):186-197. PubMed ID: 33506725
[No Abstract] [Full Text] [Related]
5. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
[TBL] [Abstract][Full Text] [Related]
6. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003.
Lamb DA; Eurich DT; McAlister FA; Tsuyuki RT; Semchuk WM; Wilson TW; Blackburn DF
Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):228-35. PubMed ID: 20031842
[TBL] [Abstract][Full Text] [Related]
7. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
8. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker adherence in patients with primary versus secondary diagnosis of heart failure.
Brackbill ML; Bashaw-Keaton R; Sytsma CS
Am J Manag Care; 2007 Oct; 13(10):568-70. PubMed ID: 17927461
[TBL] [Abstract][Full Text] [Related]
11. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[TBL] [Abstract][Full Text] [Related]
12. Monitoring and adverse events in relation to ACE inhibitor/angiotensin receptor blocker initiation in people with diabetes in general practice: a population database study.
Mathieson L; Severn A; Guthrie B
Scott Med J; 2013 May; 58(2):69-76. PubMed ID: 23728750
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic treatment in dialysis patients hospitalized for cardiovascular reasons: do we follow the guidelines?
Tomaszuk-Kazberuk A; Kozuch M; Malyszko J; Bachorzewska-Gajewska H; Dobrzycki S; Musial WJ
Ren Fail; 2013; 35(2):235-42. PubMed ID: 23176538
[TBL] [Abstract][Full Text] [Related]
14. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin inhibition after myocardial infarction: does drug class matter?
Winkelmayer WC; Fischer MA; Schneeweiss S; Levin R; Avorn J
J Gen Intern Med; 2006 Dec; 21(12):1242-7. PubMed ID: 17105523
[TBL] [Abstract][Full Text] [Related]
16. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
18. Prescription drug benefits and use of guideline recommended medications by elderly Medicare beneficiaries with diabetes mellitus.
Tjia J; Briesacher BA
J Am Geriatr Soc; 2008 Oct; 56(10):1879-86. PubMed ID: 18771456
[TBL] [Abstract][Full Text] [Related]
19. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers.
Opelz G; Döhler B
Transplantation; 2014 Feb; 97(3):310-5. PubMed ID: 24492421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]